Molecular docking of alpha-enolase to elucidate the promising candidates against Streptococcus pneumoniae infection

期刊： DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, ; ()

Purpose To predict potential inhibitors of alpha-enolase to reduce plasminogen binding of Streptococcus pneumoniae (S. pneumoniae) that may lead as an......

Pregabalin-associated stuttering and frequent blepharospasm: case report and review.

期刊： DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2020; 28 (2)

Herpes zoster is an acute, painful, herpes skin disease caused by varicella-zoster virus, which may cause viral meningitis. Pregabalin has been shown ......

Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy

期刊： DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2019; 27 (2)

Background Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. Besides its promi......

JIF：2.7

Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report

期刊： DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022; 30 (1)

Glucocorticoids are used as a first-line treatment for severe alcoholic hepatitis, and albumin reduces both the number of hospitalizations and mortali......

JIF：2.933

Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation

期刊： DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2017; 25 ( )

Background: Exenatide (EXT), the first glucagon-like peptide-1 receptor agonist, has been approved as an adjunctive therapy for patients with type 2 d......

JIF：2.67

Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway

期刊： DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2017; 25 ( )

Background: Heqi San, a traditional Chinese medicine (TCM) has been reported to regulate hormone levels in patients with metabolic disease, suggesting......

JIF：2.67